Patients and Methods
All subjects were treated as outpatients and were selected during the four months before the trial from a group of 427 known diabetic patients requiring diet plus either oral therapy or insulin for proper control. Table 1 gives the characteristics of the patient group. Unfortunately, only 3 insulin-dependent patients entered the trial. The remaining 11 were all on oral anti-diabetic medication. The ages varied between 49 and 69 years (mean, 57.5) and the duration of the diabetes was between 5 and 19 years (mean, 11.5).
All patients but 2 (Patients 1 and 3) had persistent high levels of triglycerides (200 mg/100 ml or higher) in spite of good control of diabetes by diet and either drugs or insulin. In nearly every Age range: 49-69 years (mean 57.5) Duration of diabetes: 5-19 years (mean 10.0) Dr I de Salcedo patient the serum cholesterol level was also elevated. Only in I patient was the mean pretreatment cholesterol value normal (Patient 13, 237 mg/100 ml).
Every effort was made to keep diet, activity and anti-diabetic medication constant, but we are well aware of the relative difficulty of this aim, especially at a time when strong and unexpected emotional stresses were constantly acting upon this population, all but 1 (Patient 13) of whom belonged to the upper social class. The accepted criteria of effect required a reduction to within normal limits or by 35 % or more of mean pretreatment triglyceride levels. Serum cholesterol, on the other hand, had to be lowered by 15 % or more, or reduced to within normal limits.
It is obvious that in such a short trial no dramatic changes in retinopathy could be expected, but this key parameter was nevertheless regularly assessed in all cases.
Diet was individually prepared, but in general the following values were maintained: carbohydrates 200-250 g/day, proteins 70-90 g/day, and fats 20-40 g/day. On average, the daily calorific value was 1635 C. The majority of the patients had sedentary occupations, so the actual calorific deficit was less than it appears to be.
Results
On the assumption that efficacy is related to dosage, the latter must be taken into account when analysing changes in lipid levels. All patients took 800 mg daily for at least three weeks (up to Day 49 of the trial). Thereafter doses varied between 800 and 400 mg. In Fig 1, previous clinic visit, i.e. the doses that were being taken up to and including the morning on which blood was drawn for analytical assays. On days of blood sampling, gemfibrozil was always taken after the blood had been drawn.
All patients continued in the trial for at least nine weeks, and at that time the mean reduction in serum triglycerides for the group was 30 mg/ 100 ml or 12% of the mean starting value. Subsequent mean values based on 12 or fewer patients are not strictly comparable, but there is evidence that triglyceride levels were still falling in 9 of the 12 patients who continued medication beyond nine weeks, in spite of reduced doses prescribed for 4 of them. The magnitude of the reduction in serum triglyceride levels in individual patients can be measured in different ways. Either the last value can be compared with the pretreatment mean or the lowest value can be compared with the pretreatment mean.
As the pretreatment mean is usually the average of three values determined over a period of 28 days, the most objective comparative figure might be the mean of the last two values, which were determined, with two exceptions, 28 days apart. Taking this value, a mean reduction of 41.5 mg/ 100 ml or 16.6 % of the starting value was found.
Triglycerides: Table 2 shows the mean of the last two triglyceride values during medication compared with the mean value during the four-week screening period. Taking the lowest value gives a mean reduction of 63.9 mg/100 ml or 25.6%. When the last value was not the lowest (Patients 1, 3, 9 and 10) there was in every case a dosage reduction between the lowest and the last. But dosage reduction was by no means always followed by an increase in triglyceride levels.
In general it may be said that reductions in triglyceride levels in this trial are less, both absolutely and proportionally, than in the previous trial with non-diabetic subjects. In that nondiabetic population, the triglyceride decrease ranged from 23.9% at doses of 400 mg daily to 40.16% at doses of 800 mg daily. No patient in the diabetic group achieved 35% reduction in plasma triglyceride, but 9 patients had values within the normal range at the end of treatment, including 7 of the 12 who were initially abnormal. Two more very nearly achieved normality (Patients 4 and 5). Cholesterol: Table 2 shows the mean of the last two cholesterol values during medication compared with the mean value during the four-week screening period. For the whole group the mean of the last two values is 41.2 mg/O00 ml or 13.5 % lower than the pretreatment mean. The mean of lowest values is 47.5 mg/100 ml or 15.6% lower than the baseline cholesterol mean. Fig I shows the trend related to dosage and duration of treatment. The mean values showed a steadily falling trend until Day 91 of the trial. At this point 2 patients ceased treatment, and in subsequent months others followed suit, so that group means were no longer comparable. However, of those 12 patients who continued treatment beyond Day 91 (the 63rd day of medication), all but 2 showed further reduction in serum cholesterol. Patient 5 showed no further change after two more weeks, and patient 9 showed an increase from 255 to 286 and 293 mg/100 ml during two and six further weeks, respectively. These increases may have been due to reduction of dosage to 600 and 400 mg daily during the first two and the subsequent four weeks, respectively. Patient 14, however, showed continuing reduction in cholesterol levels during two consecutive periods of four weeks at only 400 mg daily.
Like the reduction in triglyceride values, these cholesterol reductions were rather less than those found in other trials using 800 mg or lower daily doses of gemfibrozil. In our first trial with non-diabetic subjects, the average decrease in serum cholesterol was 12% at 400 mg, 20% at 600 mg, and 25 % at 800 mg.
Our aim was to obtain a 15 % reduction in plasma cholesterol or a reduction to within normal limits. Five patients a6hieved the first criterion, but only three the second. It must be remembered that the upper limit of normal for our laboratory was lower than usual, i.e. 250 mg/ 100 ml. All the patients had final values below 300 mg/100 ml, although nine had values above this before treatment.
Fasting blood glucose: Table 3 shows the mean of the last two fasting blood glucose (FBG) values during medication compared with pretreatment mean values.
Several patients showed apparent marked improvement in FBG levels. Patients 1, 6 and 8 showed the most consistent reductions. After the third week of treatment, none of these 3 patients showed a FBG level less than 13% below their pretreatment mean value, and the mean of the last two determinations showed reductions of 16.8%, 34.2% and 19.4% respectively. In spite of 2 patients with almost equally marked increases in fasting blood glucose, the group as a whole showed a 5.3 % reduction when the mean of the last two values during treatment was compared with the pretreatment mean value. When the three insulin-dependent patients are excluded, the corresponding mean reduction was 8.8 %. Two of the 4 patients whose fasting blood glucose values increased during treatment were insulin-dependent diabetics. The third such patient showed little change in FBG. If gemfibrozil affects response to exogenous insulin, the effect must be a small one.
Other parameters: Table 3 Table 4 Effect of diet +placebo alone on blood cholesterol and triglycerides in obese patients (mg/100 ml) (Table 4 ) on cholesterol, triglycerides and weight was studied in a group of 8 obese subjects with high cholesterol and triglycerides. Only 1 patient had normal triglycerides but had a high cholesterol. The diet contained an average of 75 g of protein, 20 g of fat and 150 g of carbohydrates. After two months, the blood cholesterol level dropped from an average of 320 to 275 mg/100 ml (-14%) and triglycerides from 233 to 207 mg/ 100 ml (-10%), -somewhat less marked reductions than were obtained in this trial and much less than those obtained during treatment of nondiabetic patients with gemfibrozil. The average decrease in weight was 6.4 kg (Table 4 ).
Fredrickson types: The changes in triglyceride and cholesterol levels are tabulated in simplified form in Table 5 so as to illustrate the way in which response to therapy varies according to the Fredrickson type of the patients. Table 5 suggests that type Ilb patients show the greatest reduction in both triglyceride and cholesterol values, type Ila the least, and type IV intermediate reduction. In the case of cholesterol this is consistent with the general rule that the higher the initial level, the greater the fall.
The rather small reductions in the triglyceride values of the 2 type IV patients are inconsistent with the previous reports. Patient 11 achieved a 10% reduction after three weeks of treatment at 800 mg daily. In this patient, dosage should probably have been increased instead of reduced. One point of interest emerges in the case of Patient 3 in the type Ila group. Her triglyceride level increased during treatment, although it always remained well within the normal range, but her cholesterol level showed a definite though suboptimum reduction in spite of low dosage. This demonstrates that cholesterol reduction is not necessarily secondary to triglyceride reduction.
Lipoproteins: Concentrations of alpha-, betaand pre-beta-lipoproteins were recorded as percentages, and absolute values have been calculated from these and the 'total lipid' values. Fig 2 shows the results of the electrophoretic analysis as mean values for groups of patients classified as Type Ila, Ilb and IV. Total lipids diminished during treatment in every patient, although the reduction was very small in the type Ila group (2.8 %). Alpha-lipoprotein increased slightly in some patients and diminished slightly in others. The resulting group means show only small changes, although always towards reduction. Pre-beta-lipoprotein showed a reduction during treatment in every patient, even including Patient 3 who showed a small increase in serum triglycerides. As might be expected, the reduction was least (19.5%) in the type Ila group, greatest (45.2%) in the type IIb group, and intermediate (24.1 %) in the type IV patients. However, the * *, type IIa or IIb; 0 ---0, type IV latter group consisted of only 2 patients of whom one showed a 32.6 % reduction of pre-betalipoprotein and the other a reduction of only 6.9%, so the group mean cannot be regarded as reliable.
Finally, the beta-lipoprotein is the fraction that really differentiates the groups. Two of the three patients of type Ila showed an increase during treatment and the third showed no consistent change. The group mean value increased by 14.4%. All the type Ilb patients with one exception showed reductions-and many of these were substantial, so that the mean reduction for the group was 23.8 %. The 2 type IV patients showed a mean increase of 7.7 % but this obscures the fact that one of the two patients had a 17.5% increase while the other showed a reduction of 7.4%.
There is a broad correlation between the starting level of beta-lipoprotein and the direction of change in response to treatment. All patients with a starting level of 700 mg/100 ml or above showed a reduction during treatment, and all but 2 of those with a starting level of 500 mg or above also did so. Those in the type Ila group had low starting levels and those in group Ilb had high starting levels of beta-lipoprotein.
Blood pressure: In no case did the systolic or diastolic pressures show a sustained increase, although Patient 10 did show elevated levels when she attended the clinic on days 91 and 101. Most patients had the same blood pressure ± 5 mm Hg at the end of treatment as at the beginning, but 6 patients showed reductions greater than this. The explanation may probably be found in Table 6 where 5 of these 6 patients are shown to have had weight loss in excess of 4kg.
When treating non-diabetic or diabetic obese patients with diet alone, direct correlation between weight reduction and lower blood pressure levels was also observed. As is well known, this affects the systolic more than the diastolic component.
Ophthalmoscopy: Five patients showed no retinal abnormality initially and remained normal throughout. Seven patients with varying degrees of initial abnormality showed no change during the trial. Patient 10 had a blind right eye with glaucoma and retinitis proliferans, and both exudates and recent hemorrhages in the left eye. She developed a new hxemorrhage with severe eye pain during the third month of active medication. Treatment was by photocoagulation and medication was continued at constant dosage (600 mg daily) for a week after the photocoagulation, then reduced for two weeks to 400 mg daily.
At the end of this time the eye condition had improved and a dose of 600 mg daily was resumed without further changes in ophthalmoscopic appearance during the last two months of medication. This patient died two months after completion of the trial. She continued the oral antidiabetic therapy and diet. The final episode was acute pulmonary cedema secondary to myocardial infarction. Table 6 Blood pressure change and weight losa during treatment It is of interest to note that the 3 insulindependent patients responded in some ways differently from most of the others. They showed no weight loss, little if any reduction in fasting blood glucose levels (omitting these 3 from the calculation, the remainder of the group showed a mean reduction of 8.7%) and 1 of them was the only patient in the group to show an increase in serum triglyceride during treatment. It may reasonably be pointed out that this individual (Patient 3, classified type Ila) had a serum triglyceride level well within the normal range to begin with, but so did Patient 1, who nevertheless achieved a 20 % reduction.
The fact that, omitting the insulin-dependent group, all but 2 of the remaining 11 patients showed a reduction in their fasting blood glucose levels is consistent with the observation of Kissebah et al. (1976) that gemfibrozil may restore normal sensitivity to endogenous insulin in patients in whom this is initially depressed. This tendency towards normalization of metabolic processes could conceivably have contributed towards the weight loss that occurred in every one of the patients who were not on insulin, in spite of every effort to keep diet and physical activity constant.
However, it is a common observation that when patients enter a clinical trial they are psychologically motivated to adhere more strictly to the treatment conditions, especially if a diet is required. In our patients (except for Patients 8 and 10 who spontaneously 'confessed' their indiscipline) we are sure that all others followed the alimentary restriction more conscientiously, which certainly had its effect on the blood glucose levels.
It seems likely that the trend towards reduced blood pressure may be secondary to weight loss rather than attributable to any direct effect of gemfibrozil.
Conclusion
Gemfibrozil was well tolerated over periods of nine to 23 weeks at doses of 800 mg daily initially, in many cases reduced to 600 mg after the first three to nine weeks, and occasionally reduced to as little as 400 mg, eventually. At these low doses, the magnitude of the effect of the drug was less than that observed in another trial by the same investigators. The effect upon triglycerides seemed to be reduced more than did the effect upon cholesterol, compared with results in the higherdose study.
Dose reduction was sometimes but not always accompanied by evident diminution in effect. Several patients were well controlled, and two showed continuing improvement at doses as low as 400 mg daily. In this group of diabetic patients, Patient 11 initially had grade II hypertensive retinopathy with several small hemorrhages in both eyes and microaneurysms. On Day 77 of the trial (after seven weeks of active medication) the blood pressure had fallen from 195/120 to 185/105 and fewer hemorrhagic points were seen. Treatment continued only for two further weeks, but during that time the improvement was maintained.
Clinical laboratory measurements: With one exception, every patient had at least two determinations of SGOT, SGPT, alkaline phosphatase, serum bilirubin and creatine phosphokinase performed before starting active medication. In the case of Patient 10, only one set of pretreatment values is available. All these measurements were repeated at intervals during medication. The first three were carried out at least three times, and up to eight times during treatment. The last two were carried out only twice in Patient 11, but between three and seven times in all other patients.
No abnormal values were recorded, except for a single serum bilirubin level below the lower limit of normal (0.3 mg/100 ml) during the pretreatment period in Patient 9.
Abnormalities in hematological variables were all of minor degree, and the commonest was a slight elevation in the eosinophil count. This never exceeded 7.5% of total leukocytes (upper limit of normal, 3.5%) and the highest values were recorded during the control period.
Abnormalities detected in urinalysis were those to be expected in a group of diabetics, many of whom also had a degree of hypertension. Glycosuria, proteinuria and hyaline casts were all common, but in no case was there any clear indication that treatment with gemfibrozil exacerbated or ameliorated the condition.
Discussion
The fact that the patients in this trial all had diabetes does not necessarily mean that their hyperlipoproteinaemia is secondary. Indeed it is possible that prolonged hypertriglyceridwmia, by causing relative resistance to insulin, may cause maturity onset diabetes, in which case the diabetes would be secondary. However, all these liatients had direct diabetic antecedents and their abnormal lipid pattern had persisted, except for minor changes, in spite of reasonable control of the diabetic condition over prolonged periods.of time (more than six months in Patients 1, 2, 3, 4, 5, 11, 12 and 13). It is therefore reasonable to suppose that at least some of the the patients in this study had secondary hyperlipidemias, including of course the 3 youngest patients (Patients 3, 7 and 14) who were insulin-dependent. control of the diabetes was never impaired and appeared in some cases to be slightly improved by gemfibrozil. There was no evidence of undesirable interaction. Several patients who were initially hypertensive showed reductions in blood pressure, but these seemed to be associated with weight reduction.
The small number of patients, low dosage and limited duration of the treatment made it unlikely that any conclusion would emerge with regard to the effect of treatment upon retinopathy, but 1 patient did show some improvement.
Both triglyceride and cholesterol levels were reduced to the greatest extent in Type Ilb patients, least in Type Ila, and to an intermediate extent in Type IV.
Electrophoretic separation of lipoproteins produced results resembling those of ultracentrifugal analysis in respect of two fractions, but differing with regard to the third. Pre-betalipoproteins (corresponding to VLDL) were reduced in every case.
Beta-lipoproteins (corresponding to LDL) increased or diminished according to whether the initial level was low or high respectively. Alphalipoproteins (corresponding to HDL) showed on average a reduction, whereas ultracentrifugal studies have shown an increase.
There were neither clinical nor laboratory signs of toxicity. Summary A group of 14 diabetic patients was treated with gemfibrozil during a variable length of time ranging from nine to 23 weeks in order to establish if a lowering effect on the cholesterol and triglyceride levels could be achieved, as it had been in the case of another group of non-diabetic patients. The present results showed that:
(1) The drug is remarkably well tolerated.
(2) With doses ranging between 400 and 800 mg per day the magnitude of the effect of the drug was less than that observed in our previous trial with non-diabetic subjects. The effect upon triglycerides seemed to be reduced more than that upon cholesterol when compared with results in higher-dose studies.
(3) In this group of diabetic patients (3 insulin dependent, 11 maturity-onset type) control of the diabetic condition was never impaired and appeared in some cases to be slightly improved by gemfibrozil.
(4) There was no evidence of undesirable interaction with any of the anti-diabetic drugs used.
